What Regeneron Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 32 | 111 |
| Total trades | 41 | 167 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 37,165 | 505,793 |
| Disposed | 34,564 | 461,210 |
| Net activity | +2,601 | +44,583 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −50 | $781.47 | −$39.1K | 47,833 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −463 | $780.63 | −$361K | 47,883 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −380 | $779.59 | −$296K | 48,346 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −454 | $778.64 | −$354K | 48,726 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −38 | $777.76 | −$29.6K | 49,180 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −66 | $776.31 | −$51.2K | 49,218 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −376 | $775.46 | −$292K | 49,284 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −121 | $774.48 | −$93.7K | 49,660 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −224 | $773.40 | −$173K | 49,781 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −211 | $772.56 | −$163K | 50,005 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −283 | $771.56 | −$218K | 50,216 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −12 | $770.20 | −$9.24K | 50,499 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −127 | $769.30 | −$97.7K | 50,511 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −105 | $768.33 | −$80.7K | 50,638 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −192 | $767.39 | −$147K | 50,743 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −279 | $766.47 | −$214K | 50,935 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −271 | $765.39 | −$207K | 51,214 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −219 | $764.40 | −$167K | 51,485 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −25 | $763.76 | −$19.1K | 51,704 |
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14 | Open-market sale · S | −55 | $762.57 | −$41.9K | 51,729 |
Loading...